Photo of Bruce E. Sands

Bruce E. Sands

  • PROFESSOR Medicine, Gastroenterology
Print ProfilePrint Profile

Specialty

Certifications

  • Gastroenterology

Education

  • MD, Boston University

  • Residency, Internal Medicine
    Hospital of the University of Pennsylvania

  • Fellowship, Gastroenterology
    Massachusetts General Hospital

Biography

    Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease.  He joined Mount Sinai in 2010 as Chief of the Henry D. Janowitz Division of Gastroenterology.  Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn's & Colitis Center at Massachusetts General Hospital in Boston, where he most recently served as the hospital's Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School.

    A longtime advocate for the continued translational research in Crohn's disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics.  He was among the first to report the efficacy of infliximab-a drug used to treat autoimmune diseases-in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials.  Dr. Sands was also principal investigator for the landmark ACCENT II study, an international project that demonstrated the efficacy of the anti-tumor necrosis factor antibody infliximab as a long-term treatment for fistulizing Crohn's disease.

    Dr. Sands' research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island, a project that is being funded by both the National Institute of Health and the Centers for Disease Control and Prevention.,

    A leader in several major professional organizations, Dr. Sands is chair of the Clinical Research Alliance of the Crohn's Foundation of America and serves as Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA). He is an AGA Fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG). In 2006 he was named Humanitarian of the Year by the New England Chapter of the Crohn's and Colitis Foundation of America, and the Massachusetts General Physician Organization honored him for "Excellence in Action" in recognition of his distinguished patient care.

    His work has appeared in several leading peer-reviewed journals, including the New England Journal of Medicine, Gastroenterology and Gut.  Dr. Sands is also a reviewer for many prominent publications, including the New England Journal of Medicine, and is an Associate Editor for the field's leading journal, Gastroenterology.

    Dr. Sands received his medical degree at Boston University School of Medicine in Massachusetts and completed a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia.  He then completed clinical and research fellowships at the Massachusetts General Hospital. In 2001 Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.

     

Awards

  • -
    Fellow
    American Gastroenterological Association

  • -
    Fellow
    American College of Gastroenterology

  • 2010 -
    Chair, Immunology, Microbiology & Inflammatory Bowel Disease Section
    American Gastroenterological Association

  • 2007 - 2010
    Chair, Clinical Research Alliance
    Crohn's & Colitis Foundation of America

Research

New topic

Dr. Sands' research as a clinical investigator focuses on extending basic pathogenetic observations in the inflammatory bowel diseases--Crohn's disease and ulcerative colitis--to translational research and clinical trials.  I have been an active investigator in clinical trials of novel agents directed at specific pathophysiologic targets in IBD in all phases of study. His earliest clinical trial work was with infliximab, a chimeric monoclonal anti-tumor necrosis factor antibody that has revolutionized the treatment of Crohn's disease. Dr. Sands was among the first to report on the efficacy of infliximab in ulcerative colitis, later borne out in large randomized controlled trials. Dr. Sands was also overall principal investigator for a large randomized controlled trial of  infliximab in fistulizing Crohn's disease, the largest such study to date.  In addistion to his work in clinical trials, Dr. Sands's research has included extensive work in observational studies in IBD, including outcomes research and epidemiologic studies.  Most recently, he is the principal investigator of OSCCAR, the Ocean State Crohn's & Colitis Area Registry, a novel, prospective, population-based inception cohort of inflammatory bowel disease based in the state of Rhode Island.  The goals of this study are to 1) develope robust predictive models for outcomes in IBD, and 2) to elucidate the role of environmental risk factors in the onset of IBD.

 

 

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Sands during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

  • AbbVie Inc.; Abbott Laboratories; Amgen Inc.; AstraZeneca; Avaxia Biologics, Inc.; Baxter; Bristol-Myers Squibb; Dainippon Sumitomo Pharma Co., Ltd.; Elan Corporation; IMMUNE Pharmaceuticals; Janssen Biotech, Inc., formerly Centocor Biotech, Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; PureTech Ventures LLC; Sigmoid Pharma; Teva Pharmaceutical Industries Ltd.

Scientific Advisory Board:

  • Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Limited )

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Avaxia Biologics, Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

Annenberg Building Floor 5 Room 12a
1468 Madison Avenue
New York, NY 10029


Address

Annenberg Building Floor 5 Room 207cc
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-6744
Fax: 212-241-5142
New Office

Faculty Practice Associates
5 East 98th Street, 11th Fl.
New York, NY 10029

Tel: 212-241-4299
Fax: 212-426-5099
Get Directions

Office Hours:
  • Monday 9:00am - 5:00pm
  • Tuesday 9:00am - 5:00pm
  • Wednesday 9:00am - 5:00pm
  • Thursday 9:00am - 5:00pm
  • Friday 9:00am - 5:00pm
Payment Methods
  • Master Card
  • Visa
  • Personal Check
  • Cash